I-Mab, a clinical stage biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for lemzoparlimab (also known as TJC4) to initiate a phase 1 clinical trial in patients with relapsed or refractory advanced lymphoma (CXSL2000206) as part of […]

The post I-Mab receives China Nmpa Clearance to begin phase 1 trial of lemzoparlimab in relapsed/refractory advanced lymphoma first appeared on World Pharma Today.